Release Date: December 22, 2025
Expiration Date: January 26, 2026
Activity Overview
Targeted and immunologic therapies are continuing to transform the treatment landscape for patients with small cell lung cancer (SCLC) across all disease settings. In recent years, the characterization of novel treatment approaches has led to fundamental shifts in how these tumors are managed, and therapies directed against new targets have shown substantial activity.
This Community Oncology Connections™ program is a series of live online meetings focused on providing community oncologists with the latest updates to the management of SCLC, including discussions of novel approaches to maintenance therapy, immunotherapy, and the emerging role of novel targeted therapies across the treatment landscape.
This educational activity is an archive of the live presentation held on December 11, 2025.
Target Audience
This educational program is primarily directed toward community-based oncologists involved in the treatment of SCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Discuss current trial data describing novel strategies for the management of limited- and extensive-stage SCLC
- Plan strategies to prevent and proactively manage treatment-related adverse events in patients with SCLC
- Apply clinical trial evidence supporting the efficacy and safety of SCLC treatment strategies to optimally manage patients with SCLC in the second- and subsequent-line setting
Erminia Massarelli, MD, PhD, MS
Professor and Division Chief of Hematology/Oncology
Department of Medicine
University of Texas at Tyler School of Medicine
Tyler, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Natera
Parth Khade, MD
Medical Oncologist
Texas Oncology
Plano, TX
Disclosures: Parth Khade, MD, has no relevant financial relationships with ineligible companies.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.